Oxaliplatin combined with tegafur as adjuvant chemotherapy for esophageal squamous cell carcinoma

Abstract

Objective To investigate the survival benefit of patients with esophageal squamous cell carcinomas who recieved postoperative chemotherapy of tegafur combined with FT-207 radiotherapy. Methods Data from 126 patients with esophageal squamous were analyzed who undergone radical resection from January 2008 to December 2010, consisting of 92 patients underwent surgery alone and 34 patients took oxaliplatin combined with tegafur postoperatively (oxaliplatin 130 g/m2, d1, tegafur 500 mg/m2, d1-5, 21 d for a cycle, every patient received at least two cycles). Results The 1-year survival rate and 3-year survival rate was 93.5 % and 75.0 % in the surgery alone group, was 97.1 % and 76.2 % in the surgery plus postoperative chemotherapy (P=0.590). There was no significant differences in survival in the two groups, even with Cox-regression multivariate analysis and with stratifications of gender, age, tumor location, degree of cell differentiation, invasion depth, lymphatic metastasis and TNM stage. Conclusion Postoperative adjuvant chemotherapy with oxaliplatin combined with tegafur has not significantly improve the survival rate of patients with esophageal squamous cell carcinomas undergoing radical resection. It is still lack of an effective project for postoperative adjuvant chemotherapy for esophageal cancer, and it is necessary for further study. Key words: Esophageal Neoplasms; Adjuvant chemotherapy; Oxaliplatin; Tegafur